- Home
- DMAC vs UHG Comparison
DMAC vs UHG Comparison
Compare DMAC & UHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- UHG
- Stock Information
- Founded
- DMAC 2000
- UHG 2004
- Country
- DMAC United States
- UHG United States
- Employees
- DMAC N/A
- UHG N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- UHG Homebuilding
- Sector
- DMAC Health Care
- UHG Consumer Discretionary
- Exchange
- DMAC Nasdaq
- UHG Nasdaq
- Market Cap
- DMAC 310.1M
- UHG 248.7M
- IPO Year
- DMAC N/A
- UHG N/A
- Fundamental
- Price
- DMAC $6.70
- UHG $1.65
- Analyst Decision
- DMAC Strong Buy
- UHG
- Analyst Count
- DMAC 3
- UHG 0
- Target Price
- DMAC $12.33
- UHG N/A
- AVG Volume (30 Days)
- DMAC 256.1K
- UHG 620.8K
- Earning Date
- DMAC 11-12-2025
- UHG 11-06-2025
- Dividend Yield
- DMAC N/A
- UHG N/A
- EPS Growth
- DMAC N/A
- UHG N/A
- EPS
- DMAC N/A
- UHG 0.10
- Revenue
- DMAC N/A
- UHG $445,963,017.00
- Revenue This Year
- DMAC N/A
- UHG N/A
- Revenue Next Year
- DMAC N/A
- UHG N/A
- P/E Ratio
- DMAC N/A
- UHG $18.11
- Revenue Growth
- DMAC N/A
- UHG 7.51
- 52 Week Low
- DMAC $3.19
- UHG $1.60
- 52 Week High
- DMAC $7.49
- UHG $6.93
- Technical
- Relative Strength Index (RSI)
- DMAC 48.84
- UHG 20.38
- Support Level
- DMAC $6.50
- UHG $1.65
- Resistance Level
- DMAC $7.10
- UHG $4.78
- Average True Range (ATR)
- DMAC 0.29
- UHG 0.24
- MACD
- DMAC -0.03
- UHG -0.21
- Stochastic Oscillator
- DMAC 32.90
- UHG 0.30
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About UHG United Homes Group Inc
United Homes Group Inc operates as a homebuilder which operates with a land-light idea in the Southeast. The company currently has a presence in South Carolina, North Carolina, and Georgia and focuses on providing high-quality, affordable homes for the entry-level and first-move-up segments. The company has three reportable segments: GSH South Carolina, Rosewood, and Other.